First subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain
Tecentriq® subcutaneous formulation with ENHANZE® reduces treatment time to seven minutes compared to 30-60 minutes for standard intravenous infusion
Read more at prnewswire.com